B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)

Summary

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) (MONDO:0035940) is a cancer. A subtype of B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: Unknown (Worldwide) [Orphanet-validated]

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
Mondo ID	MONDO:0035940
Orphanet	585909
DOID	DOID:0080643
ICD-11	381281608
NCIT	C80331
UMLS	C5680319
MedGen	1842992
GARD	0022342
Is cancer (heuristic)	yes

Also known as: B-ALL with t(9;22)(q34.1;q11.2) · BCR-ABL1-like B-ALL · Philadelphia chromosome-like B-ALL

Data availability: 46 cell lines.

Disease family

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › precursor lymphoblastic lymphoma/leukemia › B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality › B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)

Related subtypes (5): B-lymphoblastic leukemia/lymphoma with t(v;11q23.3), B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1), B-lymphoblastic leukemia/lymphoma with hyperdiploidy, B-lymphoblastic leukemia/lymphoma with hypodiploidy, B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3)

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.